VELOCE™ cell-free Protein expression kit data library

---

Coomassie-stained SDS-PAGE showing proteins produced with our cell-free expression kit. From left (ladder 10–180 kDa) to right: IL-2, urinary trypsin inhibitor/UTI, GFP, scFv, therapeutic protein rPA, scFv–GFP fusion, Bst DNA polymerase, and T7 RNA polymerase. Yellow arrowheads mark the target bands at their expected molecular weights, demonstrating robust expression across diverse protein classes and sizes using a single formulation.

Reproducibility you can trust.
Our cell-free protein expression kit delivers consistent yields and activity across batches, so you get reliable, high-quality results every time.

Expression of an VHH–GFP–His fusion protein rises quickly from ~0.25 mg/mL at 3 h to a peak of ~0.48 mg/mL at 6 h, with a modest decline by 16 h (~0.40 mg/mL). Bars show mean ± SD, indicating reproducible performance. These data highlight same-day production and suggest 6–8 h as an optimal harvest window for maximum yield (actual yields may vary by construct).

Using primary T-cell proliferation as the readout, IL-2 generated by our cell-free protein expression kit matched the potency of leading commercial IL-2.

Dose–response ELISA (OD₄₅₀ vs antibody concentration, ~5–300 ng/mL) shows a classic sigmoidal curve with a plateau at higher concentrations, confirming that cell-free–expressed ranibizumab retains specific VEGF-A binding. The midpoint falls in the tens-of-ng/mL range (EC₅₀ depends on assay conditions such as coating density and buffers).

This consistency reduces tech-transfer risk, shortens process-validation timelines, and enables unified QC/release methods across R&D, pilot, and manufacturing.